Comparative Pharmacology
Head-to-head clinical analysis: ADASUVE versus MELLARIL S.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADASUVE versus MELLARIL S.
ADASUVE vs MELLARIL-S
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Loxapine (the active ingredient in ADASUVE) is a dibenzoxazepine antipsychotic agent that acts primarily as a dopamine D2 receptor antagonist. It also exhibits affinity for serotonin 5-HT2A, 5-HT2C, and histamine H1 receptors, and to a lesser extent, alpha-adrenergic and muscarinic receptors. The exact mechanism of its antipsychotic effect is thought to involve dopamine and serotonin receptor blockade.
Thioridazine is a typical antipsychotic that blocks postsynaptic dopamine D2 receptors in the mesolimbic pathway, also exhibiting alpha-adrenergic blockade and anticholinergic effects.
Inhalation: 10 mg as a single dose via oral inhalation up to a maximum of 2 doses within a 24-hour period, each dose separated by at least 2 hours. For agitation associated with schizophrenia or bipolar I disorder.
Initial 50-100 mg orally 3 times daily, titrate to 200-600 mg/day in divided doses; maximum 800 mg/day for severe psychosis.
None Documented
None Documented
Mean terminal half-life of loxapine is 6-8 hours; active metabolite 7-hydroxyloxapine (amoxapine) has half-life of ~30 hours. Clinically, steady state achieved within 3-5 days.
Terminal elimination half-life: 10–20 hours (mean ~15 hours). Clinical context: Steady-state achieved within 4–5 days; allows once-daily or twice-daily dosing.
Primarily renal (30-40% as unchanged drug and metabolites; ~50% as loxapine metabolites), with minor biliary/fecal elimination (<10%).
Primarily renal (approximately 70%) as metabolites (sulfoxides and glucuronides); about 30% excreted in feces via bile. Less than 1% excreted unchanged.
Category C
Category C
Antipsychotic
Antipsychotic